Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting

World News: . []

MENLO PARK, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that promising initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be presented in a poster discussion session at the 2019 ASCO Annual Meeting in Chicago, Illinois, May 31-June 4, 2019. 

The accepted abstract is now available online on the ASCO website: .

Forty Seven’s Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of AML and MDS is funded in part by a research grant awarded by the California Institute for Regenerative Medicine (CIRM).

Forty Seven will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to review the initial clinical data presented at ASCO for 5F9. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at . A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.

Forty Seven’s Chief Executive Officer, Mark McCamish, M.D., Ph.D., and Founder and Vice President, Clinical Development, Mark Chao, M.D., Ph.D., will present on the Company’s approach to drug development at an event hosted by MATTER on Thursday, May 30, 2019 beginning at 6:00 p.m. CT (7:00 p.m. ET). The event, titled “The Current and Future Wave of Immuno-oncology Therapies,” will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at .

For journalist enquiries please contact Sarah Plumridge at or phone (312) 506-5219.

For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at or phone (212) 362-1200.

More news and information about Forty Seven, Inc.

Published By:

Globe Newswire: 22:01 GMT Wednesday 15th May 2019

Published: .

Search for other references to "forty" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us